Overview of anticoagulant drugs for the future.
More efficacious, safer, and easier to use anticoagulants are under development. Multiple agents have been shown to be effective in ex vivo or animal thrombosis models and several have progressed to clinical studies. Investigators have not yet determined if pharmaceuticals that inhibit coagulation factor activity earlier in the cascade (for example, inhibitors of tissue factor/factor VIIa, factor IXa, or Xa) are superior to those that block the cascade at a later point. Orally bioavailable drugs for the long-term treatment of thrombotic disorders, particularly those that do not require monitoring, are needed and are under development. Local delivery of anticoagulants or genes modulating anticoagulant control at sites of increased thrombogenicity, such as in diseased arteries, is a promising treatment modality that may decrease systemic bleeding problems. Much about the initiating pathophysiologic events leading to venous thrombotic disease needs to be elucidated before such local therapy can be tested in the venous vasculature. While awaiting better anticoagulants to become routinely available, we need to improve patient management with existing drugs by instituting anticoagulation clinics, promoting patient self-monitoring, and improving efforts to educate patients and health care providers about the use of anticoagulant drugs.
Department of Medicine, Division of Hematology-Oncology, Center for Thrombosis and Hemostasis, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7035, USA.
Stephan
S
Moll
Harold R
HR
Roberts
D000925:Anticoagulants / Q000494:pharmacology / Q000600:supply & distribution / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D005544:Forecasting; D006801:Humans; D013927:Thrombosis / Q000188:drug therapy
D000925:Anticoagulants